Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05924880 | A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)(TopDouble) | completed | Phase 3 | 116 | AstraZenecaINDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer(SCope-D1) | terminated | Phase 1 | 18 | AstraZenecaINDUSTRY |
| 4 |
| Apr 17, 2025 |
| clinicaltrials |
| NCT00516724 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel | completed | Phase 1 | 189 | AstraZenecaINDUSTRY | 3 | Apr 11, 2025 | clinicaltrials |
| NCT05945108 | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER | completed | — | 400 | AstraZenecaINDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04630756 | AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 9 | Apr 9, 2025 | clinicaltrials |
| NCT04236414 | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 6 | Apr 4, 2025 | clinicaltrials |
| NCT05905939 | HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia | completed | — | 774 | AstraZenecaINDUSTRY | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05790304 | Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects | completed | Phase 1 | 22 | AstraZenecaINDUSTRY | 3 | Mar 25, 2025 | clinicaltrials |
| NCT06457854 | Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone(PROCeed-BR) | withdrawn | — | 0 | AstraZenecaINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04330040 | Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer(SOLI) | completed | Phase 4 | 202 | AstraZenecaINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04023812 | Stage III NSCLC RWE in Chinese Patients | completed | — | 500 | AstraZenecaINDUSTRY | 1 | Feb 18, 2025 | clinicaltrials |
| NCT00753545 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | completed | Phase 2 | 265 | AstraZenecaINDUSTRY | 17 | Feb 3, 2025 | clinicaltrials |
| NCT03944772 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD) | active not recruiting | Phase 2 | 247 | AstraZenecaINDUSTRY | 9 | Jan 30, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT04588298 | A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer(SERENA-3) | completed | Phase 2 | 135 | AstraZenecaINDUSTRY | 3 | Jan 24, 2025 | clinicaltrials |
| NCT05184257 | Zoladex® 10.8 BC RWS | completed | — | 1,176 | AstraZenecaINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03509012 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors(CLOVER) | completed | Phase 1 | 105 | AstraZenecaINDUSTRY | 5 | Jan 14, 2025 | clinicaltrials |
| NCT04249362 | Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy(DUART) | completed | Phase 2 | 102 | AstraZenecaINDUSTRY | 6 | Jan 10, 2025 | clinicaltrials |
| NCT02151981 | AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer(AURA3) | completed | Phase 3 | 421 | AstraZenecaINDUSTRY | 18 | Jan 7, 2025 | clinicaltrials |
| NCT04712903 | Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer(CANTABRICO) | completed | Phase 3 | 101 | AstraZenecaINDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | terminated | Phase 1 | 7 | AstraZenecaINDUSTRY | 7 | Jan 7, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT05008055 | Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma(CAPITAL) | completed | Phase 2 | 30 | AstraZenecaINDUSTRY | 7 | Dec 20, 2024 | clinicaltrials |
| NCT02398747 | Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04818632 | AZD9833 China PK Study(AZD9833) | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03995875 | Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC(AYAME) | completed | — | 529 | AstraZenecaINDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04449861 | Durvalumab Plus Chemotherapy in ES-SCLC (Oriental) | completed | Phase 3 | 166 | AstraZenecaINDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04930536 | Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma | completed | Phase 4 | 103 | AstraZenecaINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04989816 | Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens(DG-06) | completed | Phase 2 | 95 | AstraZenecaINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05592483 | An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer(DB RESPOND) | terminated | — | 78 | AstraZenecaINDUSTRY | 9 | Nov 7, 2024 | clinicaltrials |
| NCT02094261 | Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours(AURA2) | completed | Phase 2 | 210 | AstraZenecaINDUSTRY | 8 | Nov 6, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT03239340 | A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib(ELIOS) | completed | Phase 2 | 154 | AstraZenecaINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT05397171 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | terminated | Phase 1 / Phase 2 | 17 | AstraZenecaINDUSTRY | 2 | Oct 1, 2024 | clinicaltrials |
| NCT05775549 | A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer(FLAME) | completed | — | 24 | AstraZenecaINDUSTRY | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02454933 | Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours(CAURAL) | completed | Phase 3 | 29 | AstraZenecaINDUSTRY | 3 | Sep 19, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT05140382 | AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL | completed | Phase 2 | 52 | AstraZenecaINDUSTRY | 8 | Aug 28, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT03421353 | AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer | completed | Phase 1 | 76 | AstraZenecaINDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04529564 | Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA) | completed | — | 106 | AstraZenecaINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05469919 | An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies | completed | Phase 1 | 12 | AstraZenecaINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)(CALLA) | completed | Phase 3 | 770 | AstraZenecaINDUSTRY | 15 | Jul 26, 2024 | clinicaltrials |
| NCT04854590 | IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer | completed | — | 248 | AstraZenecaINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials